New rules for German biosimilars on the cards
This article was originally published in Scrip
Executive Summary
It looks as though regulations aimed at driving uptake of biosimilars could be introduced in Germany, according to Mathias Heck, Brussels representative for the BPI, which represents the German pharmaceutical industry.